Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2/PHASE3
200 participants
INTERVENTIONAL
2020-06-16
2020-12-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Remdesivir Efficacy In Management Of COVID-19 Patients
NCT04853901
Remdesivir in Adults With Covid-19: Mansoura University Hospital Experience
NCT04728880
The Efficacy of Ivermectin in Larger Doses in COVID-19 Treatment
NCT04351347
Sofosbuvir Containing Regimens in Treatment of COVID 19 Patients
NCT04497649
Efficacy of Faviprevir in COVID-19 Treatment
NCT04351295
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Remdesivir
Remdesivir with standard of care treatment standard of care treatment
Remdesivir
Remdesivir as antiviral drug
Standard of care treatment
Standard of care treatment
Standard of care
Standard of care treatment alone.
Standard of care treatment
Standard of care treatment
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Remdesivir
Remdesivir as antiviral drug
Standard of care treatment
Standard of care treatment
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Tanta University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Sherief Abd-Elsalam
assistant professor of tropical medicine and infectious diseases
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Sherief Abd-Elsalam, ass. prof.
Role: PRINCIPAL_INVESTIGATOR
Tanta University Faculty of medicine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Tanta university hospital, Assuit University, Ainshams University
Tanta, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Grundeis F, Ansems K, Dahms K, Thieme V, Metzendorf MI, Skoetz N, Benstoem C, Mikolajewska A, Griesel M, Fichtner F, Stegemann M. Remdesivir for the treatment of COVID-19. Cochrane Database Syst Rev. 2023 Jan 25;1(1):CD014962. doi: 10.1002/14651858.CD014962.pub2.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
COVID 19 treatment
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.